Welsh S, Zhang Y, Smith R
Clin Kidney J. 2025; 18(3):sfaf022.
PMID: 40052168
PMC: 11883229.
DOI: 10.1093/ckj/sfaf022.
Duan Z, Li J, Cai G, Wang S, Tang X, Hou W
BMC Nephrol. 2025; 26(1):85.
PMID: 39966764
PMC: 11837633.
DOI: 10.1186/s12882-025-04010-9.
Magliulo E, Ravipati P
Glomerular Dis. 2024; 4(1):200-210.
PMID: 39618492
PMC: 11606624.
DOI: 10.1159/000542354.
Culek C, Nester C
Kidney360. 2023; 4(11):1615-1622.
PMID: 37907434
PMC: 10695638.
DOI: 10.34067/KID.0000000000000260.
Xu F, Zhang C, Zhang M, Zhu X, Cheng S, Cheng Z
Int Urol Nephrol. 2023; 56(4):1475-1485.
PMID: 37845399
PMC: 10924015.
DOI: 10.1007/s11255-023-03831-7.
Autoimmunity in Infection-Related Glomerulonephritis.
Grace Choung H, Grewal R
Glomerular Dis. 2023; 3(1):32-41.
PMID: 36816426
PMC: 9936758.
DOI: 10.1159/000528712.
Infection-Related Glomerulonephritis.
Khalighi M, Chang A
Glomerular Dis. 2023; 1(2):82-91.
PMID: 36751423
PMC: 9677723.
DOI: 10.1159/000515461.
Challenges in diagnostic testing of nephritic factors.
Michels M, Volokhina E, van de Kar N, van den Heuvel L
Front Immunol. 2022; 13:1036136.
PMID: 36451820
PMC: 9702996.
DOI: 10.3389/fimmu.2022.1036136.
The Rational Use of Complement Inhibitors in Kidney Diseases.
Fakhouri F, Schwotzer N, Golshayan D, Fremeaux-Bacchi V
Kidney Int Rep. 2022; 7(6):1165-1178.
PMID: 35685323
PMC: 9171628.
DOI: 10.1016/j.ekir.2022.02.021.
Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports.
Chehade H, Guzzo G, Cachat F, Rotman S, Teta D, Pantaleo G
Front Med (Lausanne). 2021; 8:663258.
PMID: 34381795
PMC: 8350112.
DOI: 10.3389/fmed.2021.663258.
Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis.
Uchida T, Oda T
Int J Mol Sci. 2020; 21(7).
PMID: 32276523
PMC: 7178002.
DOI: 10.3390/ijms21072595.
The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.
Defendi F, Thielens N, Clavarino G, Cesbron J, Dumestre-Perard C
Clin Rev Allergy Immunol. 2019; 58(2):229-251.
PMID: 31834594
DOI: 10.1007/s12016-019-08774-5.
Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F, Okroj M, Nozal P, Melgosa M, Sanchez-Corral P, Lopez-Trascasa M
Front Immunol. 2019; 10:886.
PMID: 31068950
PMC: 6491685.
DOI: 10.3389/fimmu.2019.00886.
C3 glomerulopathy and current dilemmas.
Ito N, Ohashi R, Nagata M
Clin Exp Nephrol. 2016; 21(4):541-551.
PMID: 27878657
PMC: 5721121.
DOI: 10.1007/s10157-016-1358-5.
Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy.
Khalighi M, Wang S, Henriksen K, Bock M, Keswani M, Meehan S
Clin Kidney J. 2016; 9(3):397-402.
PMID: 27274823
PMC: 4886922.
DOI: 10.1093/ckj/sfw032.
C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B, Chanchlani R, Riedl M, Thorner P, Licht C
Pediatr Nephrol. 2016; 31(11):2079-86.
PMID: 27008643
DOI: 10.1007/s00467-015-3311-3.
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.
Chauvet S, Roumenina L, Bruneau S, Marinozzi M, Rybkine T, Schramm E
J Am Soc Nephrol. 2015; 27(6):1665-77.
PMID: 26471127
PMC: 4884110.
DOI: 10.1681/ASN.2015040348.
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.
De Vriese A, Sethi S, van Praet J, Nath K, Fervenza F
J Am Soc Nephrol. 2015; 26(12):2917-29.
PMID: 26185203
PMC: 4657846.
DOI: 10.1681/ASN.2015020184.
Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.
Haffner K, Michelfelder S, Pohl M
Pediatr Nephrol. 2015; 30(11):1951-9.
PMID: 25986912
DOI: 10.1007/s00467-015-3111-9.
Current concepts in C3 glomerulopathy.
Thomas S, Ranganathan D, Francis L, Madhan K, John G
Indian J Nephrol. 2014; 24(6):339-48.
PMID: 25484526
PMC: 4244712.
DOI: 10.4103/0971-4065.134089.